| 000 -LEADER |
|---|
| fixed length control field |
06207nam a22004455i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20140310150254.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
130702s2013 ne | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9789400768666 |
|
978-94-007-6866-6 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC261-271 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
614.5999 |
| Edition number |
23 |
| 264 #1 - |
|---|
| -- |
Dordrecht : |
| -- |
Springer Netherlands : |
| -- |
Imprint: Springer, |
| -- |
2013. |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Reichle, Albrecht. |
| Relator term |
editor. |
| 245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Title |
Evolution-adjusted Tumor Pathophysiology: |
| Medium |
[electronic resource] : |
| Remainder of title |
The Novel Language of Tumor Biology / |
| Statement of responsibility, etc |
edited by Albrecht Reichle. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
X, 453 p. 95 illus., 87 illus. in color. |
| Other physical details |
online resource. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Preface.-I Introduction.-Communication ─ evolution ─ pathophysiology: An endogenous conjunction ─Instead of an introduction.-II Combined modularized therapies for metastatic tumors: Pointing to central problems of communication among ‘systems participators’ in tumors -- Applied systems biology for the control of metastatic cancer: Therapeutic top-down strategy for targeting the tumors’ normativity -- Targeting the proangiogenic network in angiosarcomas: Biomodulatory therapy.- Long-term results of combined modularized, immune-modulatory, angiostatic, and antiinflammatory therapy in systemically pre-treated multi-systems Langerhans cell histiocytosis.- Redirecting and modulating rationalizations of tumor-immanent normative functions in castration-resistant prostate ancer.-III Social engineering: Biomodulation, either endogenously initiated or by implementation of non-normative boundary conditions -- Non-hierarchically organized operations in malignancies: Stromal dysfunction induces hematopoetic malignancies.- Biomodulatory therapy approaches in renal clear cell carcinoma: A perspective.- Proteome analysis identified the PPARc ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.IV The tumors’ normativity: Reconstructing and operationalizing starting points for an evolution theory.- The philosophical quest of a cancer cell: Redefining existentialism.- The tumor’s normativity: Normative structures, action norms and decision maxims as therapeutic targets for tumor therapy.- Criticizable claims for the validity of communication acts in biological systems: Therapeutic implications in cancer.-V Evolution theory.- Evolution theory: Its practical relevance for understanding tumor development and specifying tumor therapy -- Modularity, subjectivity, intersubjectivity and normativity: Clinically applicable operative benchmarks -- Turning upside down the mode of science to emphasize and harness the impact of environmental communicative events. VI From genome- or organ-centric to rationalization-centric systematization of tumors -- Purposive-rational tumor therapy: Exploiting the tumor’s ‘living world’ for diversifying, specifying and personalizing tumor therapy -- Including rationalizations of tumor-associated normative notions in pathophysiologic considerations: Communication-theoretical implications.-VII Reconstruction of tumor-immanent normative functions, structures and decision maxims (hubs).- Bridging a diagnostic and therapeutic gap: Selecting, assessing and categorizing tumor-associated normative notions.- Personalizing tumor pathophysiology by diagnosing developmental problems in tumors with imaging techniques -- Biologic memory: Induction by metronomically administered combined modularized therapy.- VIII The tool of rationalizations constituting tumor-associated normative notions: The non-genomic counterpart of the tumor genome and therefore, an important therapeutic target for diversifying palliative care -- Diversifying and specifying palliative care for patients with metastatic cancer by therapeutic implementation of non-normative boundary conditions -- Targeting a hallmark of cancer: Simultaneous inflammation and tumor control for palliative care in metastatic cancer.-IX Novel clinical and pharmaceutical technology for bioengineering tumor response.- Combined modularized tumor therapy ─ tumor biology ─ and prognostic factors: Bioengineering tumor response.-X Objectifying the systems objects’ subjectivity in biological systems: A novel reification of the scientific picture about the ‘objective’ world -- The systems objects’ subjectivity as scientific object. Index. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Combined modularized therapies for metastatic cancer are pointing to central problems of communication among ‘systems participators’. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjusted tumor pathophysiology is borne by an evolution theory, which contrasts narrative evolution histories. The tool of rationalizations constituting the tumor's normativity (inflammation, immune response etc.) represents the non-genomic counterpart of the tumor genome and should be additionally assessed during tumor staging. Evolution-adjusted tumor pathophysiology allows implementing applied systems biology, a novel clinical and pharmaceutical technology for bioengineering tumor response and personalizing tumor therapy. Combined modularized therapy, evolution-adjusted tumor pathophysiology, and ‘universal’ biomarkers concertedly address genetically based tumor heterogeneity. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine. |
|
|---|
| Topical term or geographic name as entry element |
Oncology. |
|
|---|
| Topical term or geographic name as entry element |
Pharmaceutical technology. |
|
|---|
| Topical term or geographic name as entry element |
Biological models. |
|
|---|
| Topical term or geographic name as entry element |
Biomedicine. |
|
|---|
| Topical term or geographic name as entry element |
Cancer Research. |
|
|---|
| Topical term or geographic name as entry element |
Biomedicine general. |
|
|---|
| Topical term or geographic name as entry element |
Systems Biology. |
|
|---|
| Topical term or geographic name as entry element |
Pharmaceutical Sciences/Technology. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Printed edition: |
| International Standard Book Number |
9789400768659 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-94-007-6866-6 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
E-Book |
